Recombinant Human IL21 protein

中文名： 小鼠白介素21(IL21)重组蛋白
别名： IL21；Interleukin-21

货号: PA1000-4830

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>97%SDS-PAGE.
种属	Human
靶点	IL21
Uniprot No	Q9HBE4
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	23-155aa
氨基酸序列	QGQDRHMIRM RQLIDIVDQL KNYVNDLVPE FLPAPEDVET NCEWSAFSCF QKAQLKSANT GNNERIINVS IKKLKRKPPS TNAGRRQKHR LTCPSCDSYE KKPPKEFLER FKSLLQKMIH QHLSSRTHGS EDS
预测分子量	15.4 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于IL-21重组蛋白的示例参考文献(内容为模拟概括，实际文献需通过学术数据库检索确认)：

---

1. **标题**：*IL-21 enhances antitumor immune responses through direct activation of CD8+ T cells*

**作者**：Casey, K.A. et al.

**摘要**：研究证明重组IL-21蛋白通过直接激活CD8+ T细胞，显著增强抗肿瘤免疫反应，并在黑色素瘤小鼠模型中抑制肿瘤生长。

2. **标题**：*Recombinant IL-21 synergizes with anti-PD-1 therapy to improve NK cell-mediated tumor control*

**作者**：Davis, M.R. et al.

**摘要**：发现重组IL-21可增强NK细胞功能，并与PD-1抑制剂协同作用，提升实体瘤治疗的疗效，提出联合疗法的潜在临床价值。

3. **标题**：*IL-21 as a vaccine adjuvant: Induction of durable T cell responses in primates*

**作者**：Thompson, J.A. et al.

**摘要**：评估重组IL-21作为疫苗佐剂的效果，证明其能显著延长非人灵长类动物中抗原特异性T细胞应答，为感染性疾病疫苗开发提供依据。

4. **标题**：*Structure-function analysis of recombinant IL-21 and its receptor binding mechanism*

**作者**：Wang, L. et al.

**摘要**：通过晶体学解析重组IL-21蛋白结构，揭示其与IL-21受体结合的分子机制，为优化工程化IL-21变体奠定基础。

---

**说明**：以上为模拟简化版文献摘要，实际研究中建议通过PubMed、Google Scholar等平台检索关键词“recombinant IL-21”或“IL-21 protein therapy”获取具体文献。

背景信息

Interleukin-21 (IL-21) is a pleiotropic cytokine belonging to the common gamma-chain (γc) receptor family, which includes cytokines like IL-2. IL-4. and IL-7. It was first identified in the early 2000s and is primarily produced by activated CD4+ T cells, particularly follicular helper T cells (Tfh), and natural killer T (NKT) cells. IL-21 plays a critical role in modulating both innate and adaptive immune responses by binding to its heterodimeric receptor complex composed of the IL-21 receptor (IL-21R) and the γc subunit. This interaction triggers downstream signaling pathways, such as JAK-STAT, MAPK, and PI3K, influencing cellular proliferation, differentiation, and survival.

Recombinant IL-21 protein is engineered using genetic recombination techniques, typically expressed in mammalian cell systems (e.g., CHO or HEK293 cells) or prokaryotic systems like *E. coli*, followed by purification to ensure bioactivity. Its therapeutic potential stems from its ability to enhance cytotoxic T cell and NK cell functions, promote B cell differentiation into plasma cells, and regulate autoimmune responses. These properties have spurred research in cancer immunotherapy, particularly in combination with checkpoint inhibitors or adoptive cell therapies, as well as in treating viral infections and autoimmune disorders.

Preclinical studies highlight IL-21's dual role: it can suppress tumor growth by boosting antitumor immunity but may also exacerbate inflammation in autoimmune settings. Clinical trials have explored its efficacy in malignancies like melanoma and renal cell carcinoma, though challenges such as cytokine release syndrome and dose-dependent toxicity remain. Ongoing research focuses on optimizing delivery methods, including engineered fusion proteins or gene therapy, to harness its immunomodulatory effects while minimizing adverse outcomes. As a versatile tool, recombinant IL-21 continues to offer insights into immune regulation and therapeutic development.